1198098-03-1

Basic information

• Product Name: (Z)-5-(3,4-dimethoxybenzylidene)-2-iminothiazolidin-4-one
• Synonyms: (Z)-5-(3,4-dimethoxybenzylidene)-2-iminothiazolidin-4-one
• CAS NO: 1198098-03-1
• Molecular Weight: 264.305
• Mol File: 1198098-03-1.mol

Chemical Properties

• CAS DataBase Reference: (Z)-5-(3,4-dimethoxybenzylidene)-2-iminothiazolidin-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: (Z)-5-(3,4-dimethoxybenzylidene)-2-iminothiazolidin-4-one(1198098-03-1)
• EPA Substance Registry System: (Z)-5-(3,4-dimethoxybenzylidene)-2-iminothiazolidin-4-one(1198098-03-1)

Safety Data

• Hazardous Substances Data: 1198098-03-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
DABIT is used as a therapeutic agent for the treatment of various types of cancer, including breast, prostate, and colon cancer. It modulates multiple signaling pathways in cancer cells, leading to the inhibition of tumor growth and progression.
Used in Anti-inflammatory Applications:
DABIT is used as an anti-inflammatory agent for the treatment of inflammatory conditions such as rheumatoid arthritis and inflammatory bowel disease. It inhibits the production of pro-inflammatory cytokines, reducing inflammation and alleviating symptoms.
Further research is ongoing to explore the full range of DABIT's biological activities and potential applications in medicine.

Upstream product

• 120-14-9 3,4-dimethoxy-benzaldehyde 
• 556-90-1 pseudothiohydantoin 

Relevant articles and documents

A novel synthetic compound, (Z)-5-(3-hydroxy-4-methoxybenzylidene)-2-iminothiazolidin-4-one (MHY773) inhibits mushroom tyrosinase

As part of continued efforts for the development of new tyrosinase inhibitors, (Z)-5-(substituted benzylidene)-2-iminothiazolidin-4-one derivatives (1a – 1l) were rationally synthesized and evaluated for their inhibitory potential in vitro. These compound

New compounds having skin whitening, antioxidant and PPAR activity, and medical use thereof

PURPOSE: A novel compound with skin whitening, antioxidation, and PPAR activation effects, and a medical use thereof are provided to be used for a pharmaceutical composition or a cosmetic product. CONSTITUTION: A compound is denoted by chemical formula 1. A skin whitening composition contains the compound as an active ingredient. An antioxidative composition for preventing or treating oxidative diseases contains the compound of chemical formula 1 as an active ingredient. The oxidative diseases are selected among skin aging, pigmentation, wrinkling, psoriasis, or eczema. The composition prevents or treats diseases which are regulated by PPAR(peroxisome proliferator-activated receptor) activity. The PPAR includes PPAR alpha or PPAR gamma.

Design, synthesis and biological evaluation of 5-benzylidene-2-iminothiazolidin-4-ones as selective GSK-3β inhibitors

In this work, iminothiazolidin-4-one derivatives were explored as selective GSK-3β inhibitors. Molecular docking analysis was carried to design a series of compounds, which were synthesized using substituted thiourea, 2-bromoacetophenones and benzaldehydes. Out of the twenty five compounds synthesized during this work, the in?vitro evaluation against GSK-3 led to the identification of nine compounds with activity in lower nano-molar range (2–85?nM). Further, in?vitro evaluation against CDK-2 showed five compounds to be selective towards GSK-3.

NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREFOR

Provided are a novel compound having skin-whitening, anti-oxidizing and PPAR activities and a medical use thereof, and the compound has skin-whitening activities for the suppression of tyrosinase, and accordingly, is useful for use in skin-whitening pharmaceutical composition or cosmetic products; has anti-oxidant activities, and accordingly, is useful for the prevention and treatment of skin-aging; and has PPAR activities, and in particular, PPARα and PPARγ activities, and accordingly, is useful for use in pharmaceutical compositions or health foods which are effective for the prevention and treatment of obesity, metabolic disease, or cardiovascular disease.

Discovery of (Z)-5-(4-methoxybenzylidene)thiazolidine-2,4-dione, a readily available and orally active glitazone for the treatment of concanavalin A-induced acute liver injury of BALB/c mice

A large amount of evidence suggests that monocytes/macrophages infiltration is implicated in a variety of inflammatory diseases including acute liver injury. Monocyte chemoattractant protein 1 (MCP-1) plays a crucial role in the process of macrophages recruitment. We herein presented a small-molecule library and a feasible quick screening method of evaluating potency of inhibition of chemotaxis of RAW264.7 cells stimulated by MCP-1. Fifty-three small molecules were synthesized and screened, and four compounds (2g, 2h, 4f, and 6h) showed inhibitory effects with IC50 values range from 0.72 to 20.47 μM, with compound 4f being the most efficient. Further in vivo studies demonstrated that oral administration of 2g, 2h, 4f, or 6h decreases, most significantly for 4f, the serum levels of alanine aminotransaminase (ALT) and asparate aminotransaminase (AST) in ConA-induced acute livery injury BALB/c mice. Histopathological evaluation liver sections confirmed 4f as a potent, orally active compound for hepatoprotective effects against ConA-induced acute liver injury in BALB/c mice.